Companies: 10,795·Total market cap: $144.5T
Guardian Pharmacy Services, Inc.

Guardian Pharmacy Services, Inc.

GRDNNYSEHealthcare● Active
$40.51
+$0.03(+0.07%)
Market Cap$2.6B
P/E Ratio
52W High$41.36
52W Low$19.17

Guardian Pharmacy Services, Inc. (GRDN) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

grdn · stock forecast · 3 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 3 Wall Street analysts in the past 3 months

SellBuy

Buy

3 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
3
Hold
0
Sell
0
Strong Sell
0
Total: 3 · Buy rate: 100.0%

12-Month Price Target

High

$40.00

Consensus

$38.00

-6.3% upside

Low

$36.00

Median: $38 · Last Close: $40.55

The Guardian Pharmacy Services, Inc. (GRDN) analyst consensus is Buy, based on ratings from 3 Wall Street analysts over the past 3 months. The average 12-month GRDN price target is $38.00, representing -6.3% upside from the current price of $40.55.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $38 (-6.3%)

Consensus Target

$38.00

-6.3% upside

High Target

$40

-1.4%

Low Target

$36

-11.2%

Current Price

$40.55

as of today

Based on analyst price targets, the GRDN stock price prediction for the next 12 months ranges from $36 to $40. The consensus GRDN price forecast of $38.00 implies -6.3% upside from the current price of $40.55.

Short-Term Price Prediction

Bull

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$42.354.44%

1-day model range: $42.18–$42.53. Peak: $42.53 (+4.44%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$73+80.0%
2028$108+166.4%
2029$139+243.1%
2030$163+302.4%
2031+344.1%
Confidence:MediumCapped at 80% annual limit

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BULLISH

Based on 14 technical indicators

93%0%7%
13Buy
0Neutral
1Sell
RSI (14)84.7Overbought
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · GRDN · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$39.98BUY
MA 10$39.44BUY
MA 20$38.00BUY
MA 50$37.71BUY
MA 100$35.22BUY
MA 200$31.69BUY
Current $GRDN · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$40.10BUY
EMA 10$39.46BUY
EMA 20$38.63BUY
EMA 50$37.35BUY
EMA 100$35.44BUY
EMA 200$32.27BUY
Current $GRDN · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Oppenheimer2026-05-07
Maintains
OutperformOutperform
Truist Securities2026-04-13
Maintains
BuyBuy
Oppenheimer2026-03-12
Maintains
OutperformOutperform
Truist Securities2026-03-12
Maintains
BuyBuy
Stephens & Co.2026-01-14
Maintains
OverweightOverweight
Truist Securities2025-11-14
Maintains
BuyBuy
Truist Securities2025-09-26
Maintains
BuyBuy
Truist Securities2025-05-19
Maintains
BuyBuy
Truist Securities2025-04-11
Maintains
BuyBuy
Truist Securities2024-11-15
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Guardian Pharmacy Services, Inc. (GRDN) stock. Of the recent 10 rating actions, 0 were upgrades and 0 were downgrades. 3 analysts currently cover GRDN.

Analyst Recommendation Trends

Buy ratings11
Hold ratings00
Sell ratings00

GRDN analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$1.2B

↓ 13.5% YoY

Revenue Next Year

$1.4B

↑ 17.8% YoY

EPS This Year

$0.19

EPS Next Year

$0.98

↑ 408.2% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast GRDN EPS of $0.19 for the current fiscal year, based on estimates from 1 analysts. The GRDN revenue forecast is $1.2B for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The GRDN stock forecast is supported by two independent data sources: analyst consensus ratings from 3 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus GRDN price target is $38.00 (-6.3% upside), with an analyst consensus of Buy.

The GRDN short-term stock prediction for tomorrow is $42.35 (+4.44%). The GRDN stock price prediction for 2027 estimates an average of $73. The GRDN stock prediction for 2030 projects a range of $158–$168.

Guardian Pharmacy Services, Inc. trades on NYSE under the ticker GRDN. The GRDN stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

GRDN forecast · 8 questions

According to 3 Wall Street analysts, the average 12-month GRDN price target is $38.00, with a high forecast of $40.00 and a low of $36.00. The median price target is shown in the chart above when available. This implies -6.3% potential upside from the current price of $40.55.

GRDN price targetWhat is GRDN price targetGRDN analyst price targetGRDN 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.